co nyse qqq
lilli growth outlook improv cut cost
updat forecast estim jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data jul
rate updat jul
currenc amount express
valuat growth profit
methodolog valu compani
innov cultur strong financi commit
develop next gener drug set compani apart
peer fuel long-term growth follow steep
patent cliff lilli growth prospect improv
compani launch sever new blockbust patent loss
fade
lilli intern pipelin well posit mitig patent
loss next decad compani tend spend
sale financ develop effort new drug
much higher midteen industri averag robust
pipelin result lilli strong commit research
believ recent approv diabet drug trulic tradjenta
jardianc immunolog drug taltz olumi hold
highest sale potenti lilli new drug also sever lilli
late-stag cancer drug cyramza verzenio
develop blockbust addit clinic data hold
lilli strong entrench insulin product also help
compani deal patent loss unlik tradit drug
lilli insulin drug hard copi gener creat
barrier entri noninsulin produc larg
up-front invest need creat scale effici
lilli longer-act biosimilar insulin help compani
secur market share
compani take hard look bottom line
combin cost save expect top-lin growth lilli
aim reach oper margin believ
achiev pipelin success lilli expect increas
gross margin product initi greater
capac util may prove challeng
patent expir high-margin ciali alimta certain market
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
eli lilli pharmaceut compani focu neurosci
endocrinolog oncolog immunolog lilli key product includ
alimta cancer forteo osteoporosi jardianc trulic humalog
humulin diabet ciali erectil dysfunct also lilli
hold strong posit anim pharmaceut market plan
divest late
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
lilli post strong result decid divest
post strong second-quart result ahead
consensu expect plan slightli
rais fair valu estim gener competit
pressur area lilli portfolio recent
launch drug off-set headwind lead
oper revenu growth due cost-
cut lilli bottom line grew year year
expect growth rate slow next
quarter gener competit intensifi especi
erectil dysfunct drug ciali expect lilli one
fastest-grow larg drug compani industri
annual revenu growth rate next
three year remain bullish immunolog drug taltz
shown clinic superior lead tnf
drug class also lilli diabet franchis remain
well posit expect growth drug trulic
quarter slow novo nordisk clinic
stronger drug ozemp gain traction howev expect
posit outcom studi rewind trulic
second half help mitig competit pressur
overal strong posit lilli innov new drug
platform combin strong entrench
matur drug help reinforc wide moat rate
firm
tandem earn releas lilli announc
decis spin anim healthcar busi elanco
second half major synergi
human anim health busi less need
lean group stabil lilli beyond heavi
patent loss year expect lilli divest
divis within anim healthcar industri
believ elanco well posit competit
advantag standpoint valuat perspect
estim segment worth close
billion sever factor could affect valuat
overview competit dynam anim
healthcar market pleas see healthcar observ
titl deciph econom moat valuat
valuat growth profit jul
rais fair valu estim per
share base stronger sale growth sever recent
carri high margin lift overal margin structur
compani overal compani look well-posit
drive top-lin growth project annual sale
increas next decad result new
drug launch offset patent loss particular
outlook immunolog drug taltz olumi look
strong clinic data support drug becom
leader immunolog outsid immunolog expect
diabet drug jardianc trulic along cancer
drug cyramza becom increasingli import driver
cash flow particular jardianc look pois hit peak
sale project billion report
boehring ingelheim base strong cardiovascular data
anoth import point drive valuat cost
control increasingli think lilli abl meet
estim achiev oper margin
improv
outcom oper cost control depend new
revenu associ success recent launch
drug pipelin expect lilli reach goal
addit estim weight cost capit lilli
line compani peer group
larg base low volatil cash flow
divers inelast product portfolio rate lilli
uncertainti medium bit higher
pharma peer group partli high product
concentr risk surround compani pipelin
repres one fourth sale end
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
cash flow declin new product mitig gener
competit also lilli oper structur allow
cost-cut patent loss reduc margin
pressur lost high-margin drug sale overal lilli
establish product line creat enorm cash flow
need fund averag million develop
cost per new drug addit compani power
distribut network set compani strong partner
smaller drug compani lack lilli resourc lilli
entrench insulin franchis creat ad layer
competit advantag
competit seem mani year away due complex
gain gener approv insulin high cost
build need economi scale insulin product
given deceler patent loss strong pipelin
believ moat trend stabl next three
year compani key patent loss includ erectil
dysfunct drug ciali cardiovascular drug effient
potenti cancer drug alimta patent loss
next three year affect close total sale
compani strong pipelin combin stabl current
market drug lead annual revenu
growth period pipelin side
expect billion peak annual sale psoriasi
drug taltz rheumatoid arthriti drug olumi also
strong cardiovascular data lilli diabet drug
jardianc approv drive drug peak
annual sale billion
macro environ lilli sever headwind
make solid strateg move address challeng
neg side risk-sensit food drug
administr gener approv safe drug
drug high-ne area cancer also
managed-car organ pharmaci benefit
manag consolid past decad
use grow size demand lower drug price
fair valu estim bull case
probabl bear case probabl project
fair valu estim rel base case
scenario analysi show moder varianc henc
medium uncertainti rate factor affect
scenario analysi includ degre success
brand drug pipelin magnitud market
pressur current market drug larg amount
valuat driven pipelin success new drug
launch clinic trial amplifi impact lilli
patent economi scale power distribut
drug carri strong price power enabl firm
gener return invest capit excess cost
capit patent give compani time
develop next gener drug gener
mean compani top drug repres moder
amount total sale largest drug humalog
repres total sale set manag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
reduc coverag less innov drug forc drug
firm push true innov reduc power
lilli distribut network govern
evalu compar effect program
aggress price negoti rais bar futur
innov lilli sever headwind pipelin
hold sever biolog drug hold much stronger
competit advantag tradit small molecul
compani pipelin focus
innov treatment area unmet medic need
payer coverag price power remain strong
outsid pipelin compani strong insulin franchis
sale carri extra protect award
biolog economi scale need produc
rel lower-pr drug also compani
well-entrench anim health busi sale
oper matur stabl busi
experienc signific chang
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
olilli launch new immunolog drug taltz
olumi offer better efficaci stronger
safeti profil tnf drug like set
olilli divestitur anim healthcar group
enabl firm focu higher-margin human
olilli increas focu develop drug
unmet medic indic neurolog oncolog
strategi improv success rate
food drug administr drive strong price
olilli lag immuno-oncolog market may
creat competit headwind older cancer
osever lilli recent launch diabet drug
year behind competit launch
lack differenti could slow market share
oth alimta composit matter patent expir
could bring gener market
weaker patent expir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
equival begin period
total avail debt servic
oblig commit
total oblig commit
strong cash flow deriv stabl diversifi
product portfolio remain solid financi foot
expect compani debt/ebitda level fall
project level time
time also expect debt/capit ratio
fall close cash flow
accru year strong growth prospect
expect lilli need make major acquisit
drive growth nevertheless expect
acquisit augment growth compani
adjust free
gener
gener revolv adjust
commit
gener
manufactur brand-nam drugmak also
govern managed-car organ continu
consolid purchas power exert price
challeng liabil lawsuit patent risk
cancer drug alimta sale elev
patent strong composit matter patent
increas likelihood earlier-than-expect gener
competit also strong data novo new drug
like weigh growth prospect trulic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
view lilli stewardship rel standard
believ lilli use billion acquir imclon
like gener good return partnership
boehring ingelheim greatli improv strateg
outlook compani verdict still regard
lilli decis spend industry-lead amount
capit percentag sale research
develop pipelin look strong phase
data need determin return invest
lilli purchas price novarti anim healthcar
busi billion appear high increas
entrench anim health increas lilli
competit advantag well-posit industri
januari dave rick took helm
ceo follow smooth transit previou ceo
john lechleit retir rick bring strong experi
previous serv presid lilli biomedicin
group cover alzheim diseas urolog
immunolog musculoskelet diseas pain well
compani global market function rick
experi lilli date back join
compani busi develop associ dont
expect major chang transit senior
repres date owner name posit common share held report holder issuer
new jersey divis pension benefit
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
lilli post strong result decid divest
post strong second-quart result ahead
consensu expect plan slightli
rais fair valu estim gener competit
pressur area lilli portfolio recent
launch drug off-set headwind lead
oper revenu growth due cost-
cut lilli bottom line grew year year
expect growth rate slow next
quarter gener competit intensifi especi
erectil dysfunct drug ciali expect lilli one
fastest-grow larg drug compani industri
annual revenu growth rate next
three year remain bullish immunolog drug taltz
shown clinic superior lead tnf
drug class also lilli diabet franchis remain
well posit expect growth drug trulic
quarter slow novo nordisk clinic
stronger drug ozemp gain traction howev expect
posit outcom studi rewind trulic
second half help mitig competit pressur
overal strong posit lilli innov new drug
platform combin strong entrench
matur drug help reinforc wide moat rate
firm
tandem earn releas lilli announc
decis spin anim healthcar busi elanco
second half major synergi
human anim health busi less need
lean group stabil lilli beyond heavi
patent loss year expect lilli divest
divis within anim healthcar industri
believ elanco well posit competit
advantag standpoint valuat perspect
estim segment worth close
billion sever factor could affect valuat
overview competit dynam anim
healthcar market pleas see healthcar observ
titl deciph econom moat valuat
lilli strong tanezumab data
report posit top-lin phase data
pipelin pain drug tanezumab rel clean side
effect profil support above-consensu
expect drug under-valued call
stock project tanezumab sale billion
ahead consensu estim close million
side effect plagu tanezumab nerv
growth factor class past believ current
clinic studi better manag side effect
overal strong clinic data help reinforc
phase studi treat osteoarthr pain
sign osteonecrosi less rate rapidli
progress osteoarthr believ support
chanc approv drug
treat
osteoarthr pain howev detail around sever
level side effect disclos like
come later year find lack osteonecrosi
break bone tissu encourag side
effect major reason clinic hold class
drug close six year ago efficaci side
primari
endpoint consist histor studi
expect sever phase studi treat pain relat
osteoarthr lower back cancer read
next month probabl approv
treat osteoarthr pain probabl
approv treat lower back pain project annual peak
sale billion
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
complet review ngf market outlook
tanezumab pleas see report pain potenti
lot lilli regeneron also report
lilli regeneron address unmet need chronic pain
market provid insight thoma schnitzer md phd
outlook ngf class
decreas forecast fve jun
margin lower fair valu estim incyt
per share incorpor food
drug administr approv olumi baracitinib
mg dose mg dose propos
partner amid safeti concern limit approv
par advisori committe recommend
releas earlier april odd approv
dose found elsewher world name europ
japan narrow moat rate remain intact believ
competit advantag rest jakafi franchis
rare blood disord unrel olumi
slightli lower top-lin estim olumi
 market smaller dose could limit usag
drug among sever treatment-refractori patient
could benefit potent mg dose
olumi addit black box warn thrombocytosi
found label incumb jak inhibitor
xeljanz could also temper enthusiasm drug though
lower rel seriou infect malign seen
trial could provid small window opportun incyt
lilli base posit phase result rheumatoid
arthriti popul competitor plan file anoth
oral jak inhibitor upadacitinib fda second
half would posit drug regulatori
decis notabl upadacitinib shown high
efficaci among rheumatoid arthriti patient sign
thrombot event like olumi up-and-com
expect intensifi competit
howev sale outlook alreadi dampen
follow fda complet respons letter
advisori committe mix vote last month addit
believ rheumatoid arthriti market abl
support multipl oral therapi high degre
patient churn differ therapi sinc
receiv portion olumi sale form royalti
partner lilli revis outlook minim
impact valuat rest-of-world sale europ
japan project olumi alreadi gain
approv mg remain unaffect fda limit
olumi news abrupt flash burn
ido inhibitor program believ market
overpen compani creat attract entri
point investor jakafi label expans continu
uptak among approv popul addit
progress next-gener jak inhibitor itacitinib
biggest driver valuat
trump blueprint lower drug price offer minor
chang pharma biotech moat impact
administr blueprint lower drug price reduc
out-of-pocket cost offer propos dont impact
moat rate pharma industri
price power brand drug still look
transpar provid inform help
patient lower out-of-pocket cost believ
limit impact brand drug price mild
polici propos appear larg build
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
budget propos drug white paper issu
council econom advisor februari aggreg
think propos would like impact less
drug spend exclud potenti chang
negoti medicar part drug could offer
anoth reduct drug spend depend
exact implement
overal blueprint propos creat minor headwind
brand drug price regard propos increas
gener competit view brand drug
industri tactic
limit gener competit
rel ineffect gener biolog biosimilar
larg assum swift competit follow patent
loss alreadi line polici effort
increas gener competit hard-to-mak drug
polici propos limit use risk evalu
mitig strategi delay gener competit rare
use could potenti impact drug firm
exampl celgen key drug revlimid could face
addit gener rapid launch gener
review fda
propos increas negoti around part drug
look like substant propos drug
histor face much price pressur note
drug tend least interchang
competit make negoti drug price
difficult polici propos regard incent
lower drug list price price transpar
direct-to-consum ad inform view
limit potenti reduc price lastli
focu lower out-of-pocket drug cost allow
cost-sav inform pharmacist provid
inform lower-cost altern treatment option
medicar patient could provid minor cost save
would significantli alter price power brand
within polici propos beyond immedi
action outlin administr provid
opportun explor addit cost save
granular propos limit view
major addit opportun focus
close rel smaller price loophol explor
altern price model value-bas
reimburs new strategi around medicaid drug
price believ innov brand drug
abl thrive environ major current
brand drug develop alreadi focus
innov meet increas demand privat sector
payer pharmaci benefit manag pbm
addit two opportun explor could
significantli help brand drugmak first propos
limit abil pbm reli rebat drug firm
lower drug cost could forc transpar
upfront price discount potenti give drug firm
power set price second effort make
countri pay drug hold potenti increas
global price power view initi larg
polit driven difficult implement
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued
trump drug look modestli lower drug price
keep pharma biotech moat intact may
trump polici speech lower drug price didnt offer
mani specif focus mostli reduc middleman
profit rais drug price oversea base
 govern budget propos council
econom advisor white paper drug polici expect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
modest neg headwind brand drug price
continu view moat within pharma/biotech
industri intact support strong price power
patent protect drug view brand drug group
aggreg under-valued expect group digest
modest price headwind major impact
valuat view roch sanofi allergan
under-valued wide moat drug firm
biggest neg seen administr
propos shift medicar part drug part
scenario price decreas drug
pharma earn would like fall close
heavier hit firm exposur
drug channel regeneron beyond
polici modestli neg polici propos includ
test new price program medicaid modifi
exclus rule increas gener competit
increas medicar part negoti power
modifi payment structur medicar part
exclud shift part medicar
estim save initi look like less
 drug spend
posit polici propos brand drug
offer well implement seem unlik
notabl demand countri pay drug
seem difficult implement also break
pharmaci benefit manag increas competit would
like give drug compani power drug price
howev either polici implement
would expect major windfal brand drug industri
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
write incyt ido adcom flop
incyt ido inhibitor flop conflict baracitinib
advisori committe recommend april believ
market over-pen stock first-quart
earn reiter firm prior tribul addit
confirm end nearli late-stag ido
inhibitor studi merck bristol astrazeneca
checkpoint inhibitor expect chang
per share fair valu estim
valuat alreadi exclud futur sale epacadostat
combo incorpor temper baracitinib growth
adjust oper expens fall line
gener jakafi sale provid much-need buffer
allow compani weather two major setback
healthi year-over-year jakafi growth first
quarter rest-of-world sale follow suit underscor
confid franchis narrow econom moat
incyt manag confirm pivot trial test
epacadostat combin partner checkpoint
inhibitor halt save two pivot trial
merck keytruda lung cancer convert
fall line decis remov ido combin
sale estim model compani plan
evalu epacadostat non-checkpoint inhibitor
combin variou indic low
expect ido inhibitor class given
direct benefit favor epacadostat found
fail trial stand newlink bristol
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
larg scrap in-hous ido inhibitor
molecul indoximod respect
reinforc bleak outlook class
despit pessim ido inhibitor still view
ido favor
result
rheumatoid
arthriti patient approv dose threw
salt fresh ido wound howev sale
expect alreadi mute respons fda
complet respons letter lilli first file
believ ra market highli competit
anoth oral jak inhibitor xeljanz market anoth
promis candid work howev
given variou safeti issu surfac among current
risk seriou
infect thrombocytosi well high churn
patient differ therapi believ market
abl support multipl oral drug treatment
decis fda expect june believ
could implic fate baricitinib
immunolog popul said dont
expect launch baricitinib europ
dose alreadi approv olumi
affect regulatori decis
pipelin beyond epacadostat baricitinib still
pack arsen opinion compani expect
file jakafi label expans steroid-refractori acut
graft-versus-host-diseas bodi reject donor
cell transplant back half year fda
approv would expand popul jakafi-elig
patient coupl thousand next-gener jak
inhibitor itacitinib also expect report top-lin data
larger treatment-nav acut graft-versus-host-diseas
next year pivot data bile duct cancer drug
expect second half
buoy new drug expens control lilli post
strong result look under-valued apr
post strong first-quart result ahead
expect consensu dont
expect major shift fair valu estim base
minor out-performance continu see lilli
under-valued invest commun fulli
appreci compani new product launch
improv also
compani strong recent drug launch continu support
wide moat rate firm
top line total sale increas oper
driven sever new drug launch continu
drive sale next three year despit upcom
patent loss older drug product launch sinc
repres fourth total sale
grow close year year compani good
posit grow top line despit patent loss erectil
dysfunct drug ciali neurosci drug strattera
cardiovascular drug effient next two year
remain bullish recent launch immunolog drug taltz
despit inventori destock quarter lead
lower sale project continu expect
drug develop major blockbust base superior
efficaci better side effect profil versu older tnf
drug addit drug trulic continu post
strong growth expect growth
slow significantli next two year competitor
novo nordisk launch slightli better drug ozemp
dont expect trulic lose much market share well-
control diabet patient alreadi trulic expect
novo larg target new patient start ozemp
base larg potenti class lastli
expect immunolog drug olumi develop
blockbust recent food drug administr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
panel concern cardiovascular side effect lead
slight decreas project drug
margin side lilli continu make progress toward
oper margin guidanc
expect firm achiev goal base
strong drug launch offer oper leverag
expect major recent launch drug carri
strong margin reach blockbust statu
complet overview lilli current market drug
pipelin pleas see healthcar observ steadi
pipelin off-set gener threat secur
conflict adcom vote creat headwind
lilli ra drug share under-valued apr
rheumatoid arthriti drug baricitinib
market olumi europ plan slightli
lower top-lin sale estim drug
expect impact margin neg impact
incyt per share fair valu estim immateri
impact lilli per share fair valu estim
narrow moat rate remain intact base
compani jakafi franchis rare blood cancer
unaffect vote
efficaci once-daili oral baricitinib
mg mg dose acknowledg nearli
unanim vote committe inadequ data rule
safeti imbal name thrombot event
placebo treatment arm ultim led
recommend mg dose reject
risk-benefit profil mg dose lower seriou infect
cancer rate seen baricitinib current
-approv jak inhibitor xeljanz could given
lilli drug edg competitor reach
 market opinion howev baricitinib
unclear safeti result regard thrombot event
flag xeljanz trial could muddi advantag
baricitinib member committe note
chanc seriou thrombot event
baricitinib-tr patient actual deviat
incid found gener rheumatoid arthriti
popul howev lack conclus safeti data
sway mani committe member vote toward
recommend mg dose
believ market larg bake sub-optimal
expect baricitinib follow complet respons
letter food drug administr fda
expect drug reach market believ
commerci opportun could constrain
approv label -- recommend dose mg versu
effect mg safeti warn fda
requir follow advisori committe recommend
introduc uncertainti gener fall line
guidanc believ incyt stock still look
under-valued increas interest compani
takeout target level
guidanc lead minor fve increas jan
eli lilli fourth-quart out-performance versu
consensu expect combin tax-rat guidanc
basi point expect like lead
minor fair valu estim increas view stock
slightli under-valued lilli strong new drug growth
reinforc convict firm wide moat rate
innov offset gener competit older
quarter new drug ad million
increment sale lilli total sale billion
oper offset gener pressur
expect posit trend continu next five
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
year area strength includ immunolog drug taltz
olumi diabet drug trulic jardianc
carri stronger efficaci safer side-effect profil
older market drug howev expect trulic
sale flatten novo nordisk launch ozemp
carri slightli stronger clinic data
bottom line lilli continu hold oper cost
flat even growth top line expect
trend continu next two year strong
oper leverag partli driven less demand
pipelin given strong line-up recent launch drug
well specialty-focus sale outreach
addit tax reform also add bottom-
line margin reduc core tax rate basi point
rel lilli initi guidanc basi point
lower project
lilli expect make strateg decis elanco
anim health busi believ
divestitur like major synergi
human anim health busi less need
lean group stabil lilli beyond heavi
patent loss year expect lilli split
complet overview lilli current market drug
pipelin pleas see healthcar observ steadi
pipelin off-set gener threat secur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
